NCT00857025 is a Phase 1 clinical trial of beta-glucan MM-10-001 in Lung Cancer, sponsored by City of Hope Medical Center.

Who is sponsoring NCT00857025?

NCT00857025 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT00857025?

Interventions in NCT00857025: beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis, questionnaire administration.

What condition does NCT00857025 study?

NCT00857025 studies Lung Cancer.

Is NCT00857025 still recruiting?

NCT00857025 is currently completed. Last updated 10 August 2021.

Last reviewed 2021-08-10 · How we verify

NCT00857025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed Phase 1 Last updated 10 August 2021

What this trial tests

Phase 1 trial testing beta-glucan MM-10-001 in Lung Cancer in 20 participants. Completed in 18 May 2021.

Timeline

21 November 2008

Primary endpoint
24 November 2010

18 May 2021

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	21 November 2008
Primary completion	24 November 2010
Estimated completion	18 May 2021
Sites	1 location across United States

Drugs / interventions tested

beta-glucan MM-10-001 — full drug profile →
flow cytometry
laboratory biomarker analysis — full drug profile →
questionnaire administration

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan in treating patients with locally advanced or metastatic non-small cell lung cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application.
Murphy EJ, Rezoagli E, Major I, Rowan NJ, et al · · 2020 · cited 121× · PMID 33322069 · DOI 10.3390/jof6040356
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.
Cotechini T, Atallah A, Grossman A. · · 2021 · cited 49× · PMID 33924237 · DOI 10.3390/cells10040960
From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases.
Caseiro C, Dias JNR, de Andrade Fontes CMG, Bule P. · · 2022 · cited 40× · PMID 35328577 · DOI 10.3390/ijms23063156
The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer.
Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. · · 2020 · cited 27× · PMID 33105656 · DOI 10.3390/ijms21217820

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00857025 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00857025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing